950 Winter Street
About Radius HealthRadius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
October 3, 2003
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
Please click here for Radius Health job opportunities.
Please click here for clinical trial information.
165 articles with Radius Health
Radius Health Announces Engagement With Myrtle Potter & Company For Development Of Abaloparatide Commercialization Strategy
Radius Health To Announce First Quarter 2015 Financial Results, Host Conference Call And Live Webcast On May 6, 2015
Radius Health Today Announced That It Has Appointed Brent Hatzis-Schoch As Senior Vice President And General Counsel
Radius Health Announces Upcoming Oral Presentation "Treatment With Abaloparatide Significantly Reduces Wrist Fractures Compared To Teriparatide" In The HOT TOPICS Session At The ECTS-IBMS 2015 Congress On April 28, 2015
Radius Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan, And Has Hired Dinesh Purandare, Former Sanofi Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius
Radius To Announce Fourth Quarter And Full Year 2014 Financial Results, Host Conference Call And Live Webcast On March 10, 2015
Radius To Present At 2015 Biotechnology Industry Organization (BIO) CEO Investor Conference To Be Held February 9th & 10th In New York City
Radius Announces Oral Presentation Of The ACTIVE Phase 3 Clinical Trial Of Abaloparatide-SC For Postmenopausal Women With Osteoporosis At The International Society Of Endocrinology And The Endocrine Society (ICE/ENDO 2015)